Cindy Womack | SIU School of Medicine

About me

Cindy Womack, DNP, FNP-BC, CNRN is a Nurse Practitioner in the Department of Neurology, specializing in Alzheimer's disease and dementia care. Prior to coming to SIU School of Medicine she maintained a private practice as a Geriatric Care Manager working with older adults and their families and advocating for quality eldercare in community settings.

Gender

Female

Education & training

Positions

Certified Nurse Practitioner

Family Nurse Practicioner

Neurology

Board Certifications

Certified Neuroscience Registered Nurse

Family Nurse Practitioner

Undergraduate Degree

Southern Illinois University, Edwardsville, IL - Masters of Nursing

Download my CV

Research

Research Interests

Alzheimer's Disease, Dementia, Caregiver stress/burden

Clinical trials

Trial

Neurology

Roche: An open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease

Active not recruiting

POST GRAD: The purpose of this study is to compare the effects, good or bad, of long term gantenerumab on subjects with prodromal or mild Alzheimer's disease.

Trial

Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

Trial

Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.

Trial

Neurology

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Active recruiting

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

Trial

Neurology

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Active recruiting

ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

Cindy Womack, DNP, FNP-BC, CNRN

About me

Gender

Education & training

Research

Clinical trials

Roche: An open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

Related articles

SIU School of Medicine receives major gift for Alzheimer's research